Screener
Allogene Therapeutics ALLO Business Segments — All other development costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:ResearchAndDevelopmentExpenseOtherDevelopmentCosts.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Significant operating expenses: | ||
| Cema-cel | $7,669 | $6,222 |
| All other development costs | 1,999 | 10,390 |
| Payroll | 14,444 | 19,601 |
| Facilities & IT-related spend | 6,418 | 7,319 |
| Supporting external spend | 4,372 | 5,846 |
| Other operating expenses | 11,190 | 15,813 |
| Total operating expenses | 46,092 | 65,191 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's business segments — all other development costs?
- Allogene Therapeutics (ALLO) reported business segments — all other development costs of $2M in Q1 2026.
- How has Allogene Therapeutics's business segments — all other development costs changed year-over-year?
- Allogene Therapeutics's business segments — all other development costs decreased by 80.8% year-over-year, from $10.39M to $2M.
- What is the long-term trend for Allogene Therapeutics's business segments — all other development costs?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — all other development costs has grown at a -8.8% compound annual growth rate (CAGR), from $24.46M to $20.34M.
- What does business segments — all other development costs mean?
- This metric captures the aggregate research and development spending for the company's pipeline assets excluding the lead program. It reflects the breadth of the company's early-stage innovation efforts and diversification of its clinical portfolio. Tracking this allows for an evaluation of the company's broader R&D strategy beyond its primary asset.
Ask your AI about Allogene Therapeutics's business segments — all other development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude